Market Size (2016)
2016
$23.61B
Vertical: HealthcareBase Year: 201714 Sections
Market Size (2016)
2016
$23.61B
Projected (2024)
2024
$56.49B
CAGR (2016–2024)
11.5%
11.5%Key Players
108+
This report covers Chemotherapy Market with forecasts from 2016 to 2024. 108 key companies are profiled.
The Chemotherapy Market market is projected to grow at a CAGR of 11.5% from 2016 to 2024.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansChemotherapy is one of the types of cancer treatment which includes the use of one or more chemotherapeutic agents such as anti-cancer drugs. The treatment prevents the division of cancer cells and the growth of cancer cells by killing dividing cells. It is used for the treatment of various types of cancers such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others.
Note: The market for chemotherapy is exclusively focused on chemotherapy drugs and does not include drugs used for combination therapies such as targeted therapy, hormonal therapy and supportive care.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2016 – 2017
Forecast Period
2017 – 2024
Primary Interviews
150+
Historical data (2016–2017) and forecast period (2017–2024)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
The suppliers in the global chemotherapy industry are the developers of the drugs. There are a number of developers in the market providing various treatment for different applications. Due to the complexity of the diagnostic process and the government regulations on the new drug formulations for testing the efficacy and safety of the drugs, thus leading to the high amount of bargaining power of suppliers in the market. Currently, most of the approved drugs are related to oncology and focused on different types of cancer. Strategic and economic modifications from the existing Chemotherapy services can have a huge impact on the market with the other pharmaceutical, biotechnological companies, and device manufacturing companies being involved in the business. Hence the overall bargaining power of suppliers in the global chemotherapy market is high.
Bargaining Power of Buyers
The bargaining power of the buyer is considered to have a high impact on the industry. The bargaining power of the buyers assesses how easy it is for the buyers to affect the price of chemotherapy treatment. The large customer base ensures the possibility of pooling of cancer treatment by large hospitals and insurers. The price sensitivity for cancer treatment is high.
Threat of New Entrants
Threat from a new entrant is considered to have a high impact on the industry. In Porter’s Five Forces Analysis, ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. Any newer treatment has to be better at the existing first-line drugs. The existing treatments are fraught with serious side effects and their low cure rates. Thus, the emergence of a novel acting treatment will lead to faster market absorption with the least market uptake costs.
Threat of Substitutes
The threat of substitutes in the global chemotherapy market is very high. High threat of substitutes is due to the massive research and funding conducted to develop technologically advanced treatments. Cancer treatment has witnessed various therapies over the year which are proving its efficiency. For example, targeted therapies and hormonal therapies have witnessed majority usage.
Intensity of Rivalry
The degree of competition in the global chemotherapy market is high. There is a huge number of players in the market at present, and their product portfolio is quite varied from one another. The major companies are trying to develop accurate drugs to capture the major chunk of the market. Hence the level of intensity of rivalry is high now. To overcome the competition, players are engaged in partnering with the established pharmaceuticals. Moreover, the players are also developing advanced products for differentiating their brand from their competitors.
Market estimates by geography (2024)
InsightAmericas leads with $22.42B by 2024, while Asia Pacific is projected to grow fastest at a 12.1% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2017 | 2024 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $7.46B | $11.69B | $18.29B | 11.9% | 32% |
| Americas | $9.79B | $14.84B | $22.42B | 10.9% | 40% |
| Asia Pacific | $5.56B | $8.79B | $13.88B | 12.1% | 25% |
| Europe | $791.76M | $1.23B | $1.90B | 11.5% | 3% |
| Total | $23.61B | $36.55B | $56.49B | 11.5% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$56.49B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Alkylating agents | $20.36B | 11.5% | 88% |
| Mitotic inhibitors | $14.54B | 11.5% | 77% |
| Antimetabolites | $9.35B | 11.5% | 72% |
| Topoisomerase inhibitors | $5.25B | 11.5% | 85% |
| Antitumor antibiotic | $4.21B | 11.5% | 85% |
| Others | $2.78B | 11.5% | 53% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Chemotherapy Market covering market dynamics, competitive landscape, and strategic outlook.
The Chemotherapy Market market is projected to reach $56.49B by 2024, growing at 11.5% CAGR. The Alkylating agents segment holds the largest share.
Chemotherapy is a widely used cancer treatment. It is a drug therapy that prevents cancer cells from dividing and growing. In chemotherapy, a single drug or a combination of drugs is used. These chemotherapeutic drugs attack cancer cells throughout the body or targeted cancer sites when delivered through the bloodstream.
The global chemotherapy market is emerging due to the increasing prevalence of cancer, increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance.
However, the high cost of treatment and side-effects of chemotherapy are hampering the growth of the market.
Developing economies pose an opportunity for the chemotherapy market as they have undeveloped research and development sector owing to which they are unable to address upcoming health challenges. In spite of huge demand, the African region is dependent on imported medicines and other health technologies. Although there is a high requirement of treatment, poor economic conditions lead to the slow growth of the healthcare industry within the African region.
This undeveloped healthcare sector serves as an opportunity for chemotherapy drug providers as they can aim to strengthen the presence of the global chemotherapy market in developing regions.
The cost of treatment depends on the type and duration of treatment at the clinic or hospital. Chemotherapy is extensively used to treat many types of cancer. For some people, chemotherapy may be the only treatment, but the cost for chemotherapy is high. According to the Agency for Healthcare Research and Quality, patients with bone cancer hospitalized for about a week, incurring a cost of USD 19,600 per week. The cost of chemotherapy differs with chemotherapy regime used for the treatment. According to the International Health Economics and Outcomes Research, the cost of various chemotherapies are as follows:
Doxorubicin and cisplatin – USD 17,549 per patientCisplatin, ifosfamide, and epirubicin– USD 38,936 per patientDoxorubicin, cisplatin, high dose methotrexate, and ifosfamide– USD 38,404 per patient
Thus, this high cost for the treatment hampers the growth of the global chemotherapy market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 108 companies operating in the Chemotherapy Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
Celgene Corporation
Company Headquarters: New Jersey, US Founded: 1986 Workforce: 8,852 Company Working: Celgene Corporation is a global leading biopharmaceutical company focused on the development and commercialization of innovative drugs used in the treatment of cancer and inflammatory diseases. The company conducted more than 300 clinical trials for various applications such as multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer, and pancreatic cancer. It has a strong presence in North America, Europe, and Asia.
BRISTOL-MYERS SQUIBB COMPANY
Company Headquarters: New York, US Founded: 1887 Workforce: ~28,000 Company Working: Bristol-Myers Squibb Company merged with Squibb in 1989. Bristol-Myers Squibb Company is a leading pharmaceutical company committed to develop and deliver innovative biopharmaceutical products to help patients fight diseases globally. It mainly focuses on six core therapeutic areas such as oncology, musculoskeletal, virology, cardiovascular, metabolomics, and immunology.
Eli Lilly and Company
Company Headquarter: Indianapolis, Indiana, US Founded: 1876 Workforce: 42,066 Company Working: Eli Lilly and Company is an American global pharmaceutical company. The company also has offices in Puerto Rico and 17 other countries. Its products are sold in approximately 125 countries. The company is listed on the New York Stock Exchange, and its shares had been a component of the S&P 500 Index since 1971. Lilly was the first company to mass-produce penicillin, the Salk polio vaccine, and insulin. Its achievements include being one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin, Humalog, and the first approved biosimilar insulin product in the US, Basaglar. Lilly is also the world's largest manufacturer and distributor of psychiatric medications including Prozac (Fluoxetine), Dolophine (Methadone), Cymbalta (Duloxetine), and Zyprexa (olanzapine). Some of the top competitors of Eli Lilly and Company are Pfizer Inc., GlaxoSmithKline PLC, Biogen, Sanofi, and Johnson and Johnson.
F. HOFFMANN-LA ROCHE LTD
Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.
Johnson & Johnson Services Inc.
Company Headquarters: New Jersey, US Founded: 1886 Workforce: ~130,000 Company Working: Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887. Ethicon manufactures sutures, endocutters, breast care products, and energy-based products, like hand instruments, for tissue dissection. In 2016, Ethicon acquired NeuWave Medical, Inc.Johnson & Johnson is the world’s largest and broadly based healthcare company. It engages in the R&D, manufacture, and sale of products in the healthcare field. I Its pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, oncology, cardiovascular and metabolism, and pulmonary hypertension t has more than 130 years of industry experience. The company has a team of 134,000 people at 260 companies in more than 60 countries around the globe.
SANOFI
Sanofi is a UK-based global life sciences company which was incorporated in the year 2004. Sanofi is headquartered in Paris having the employee strength of more than 110,000 spread in more than 100 countries and have industrial sites in more than 40 countries. The company is committed to improve the access to healthcare and support the people to whom it serves throughout the continuum of care. Further, the company has its offerings into healthcare solutions, human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. Sanofi CEPiA is a subsidiary business unit of Sanofi that produces articaine hydrochloride in API form. It is a market leader in producing articaine hydrochloride. The company manufactures articaine hydrochloride in its high capacity FDA approved workshop. Sanofi’s Ankleshwar production plant has an export sales of Rs. 54,900 lakhs that is around 27% of their total sales in India in 2015 . Their healthcare solutions are available in more than 170 countries across the world and now Sanofi is focussing on increasing its presence in emerging countries. Their industrial network, know-how and employees deliver a wide range of health solutions to millions of individuals with high quality and safety. Some of the top competitors of Sanofi are Pfizer Inc., Merck & Co., Inc. GlaxoSmithKline Plc., Septodont, Dentsply Sirona, and Pierrel S.p.A., among others.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Chemotherapy Market